Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-01-18
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of leflunomide in treating
patients with multiple myeloma that has come back (relapsed) or has not responded to previous
treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.